Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001840315Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Director

144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | | | Name the Securities Exchange |
|--|---|---|---------------------------|----------|------------|------------------------------------|
| Common Stock | Tiger Brokers (Singappre) Pte. Ltd. 1 Raffles Place, #35-61, One Raffles Place Tower 2 Singapore U0 048616 | 3010722 | 17853581.46 | 34301926 | 05/26/2023 | NASDAQ |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

| EYEPOINT PHARMACEUTICALS, INC. |
|--------------------------------|
| 000-51122 |
| 480 PLEASANT STREET |
| SUITE B300 |
| WATERTOWN |
| MASSACHUSETTS |
| 02472 |
| 6179265000 |
| |

Ocumension Therapeutics

| Title of the Class | Date you Acquired | Nature of Acquisition Transaction | | Is this a Gift? | Date Donor Acquired | Amount of Securities Acquired | Date of | Nature of Payment * |
|-----------------------|----------------------|--|--------------------------------------|--------------------------|---------------------------|-------------------------------------|--------------|------------------------|
| Common Stock | 12/31/2020 | through a private placement from the issuer of the securities | EYEPOINT PHARMACEUTICALS, INC. | | | 3010722 | 12/31/2020 g | ood funds, |

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report 📝

144: Remarks and Signature

Remarks Date of Notice *ATTENTION*:

05/26/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

YE LIU

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)